Payment overview · 2025
General Payments
$162,067.70
156 reported records · 6 companies
Healthcare provider profile · identity verified
Damian E Grovas-Abad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAN JUAN, PR · NPI 1992900849
Verified facts
What the public records show
CMS Open Payments records show Damian E Grovas-Abad, M.D. received $162,067.70 in general payments during 2025 across 156 reported records.
Abbott Laboratories accounted for 65.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $106,423.15 | 65.7% | 94 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44,834.17 | 27.7% | 36 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$10,606.54 | 6.5% | 22 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $106.35 | 0.1% | 2 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $69.90 | 0.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.59 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $113,775.00 | 17 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,875.00 | 11 |
| Food and Beverage | $4,397.68 | 126 |
| Travel and Lodging | $20.02 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $56,615.31 | 42 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $37,000.00 | 5 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $16,000.00 | 5 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $16,000.00 | 4 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $11,875.00 | 2 | 2025 |
Source payment records
|
|||||
| XIENCE V Normalized: xience v |
Device | Abbott Laboratories | $8,500.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $3,110.32 | 5 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $2,505.19 | 6 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $1,114.52 | 35 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $457.24 | 9 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $355.25 | 15 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $281.03 | 7 | 2025 |
Source payment records
|
|||||
| General - CT_IC Normalized: general ct ic |
Device | Boston Scientific Corporation | $146.68 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $126.29 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $76.06 | 4 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $73.39 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $69.90 | 1 | 2025 |
Source payment records
|
|||||
| ACCESS Normalized: access |
Device | Terumo Medical Corporation | $32.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $21.19 | 2 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $15.63 | 2 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $6.10 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZ GOOSE NECK Normalized: amplatz goose neck |
Device | Medtronic, Inc. | $3.75 | 1 | 2025 |
Source payment records
|
|||||
| ASSURANT COBALT Normalized: assurant cobalt |
Device | Medtronic, Inc. | $3.46 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $0.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 947 | 372 |
| Cilostazol | Cilostazol | 454 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 129 | 48 |
| Xarelto | Rivaroxaban | 99 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 66 | 19 |
| Losartan Potassium | Losartan Potassium | 45 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 14 |
| Carvedilol | Carvedilol | 38 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 23 |
| Chlorthalidone | Chlorthalidone | 35 | 18 |
| Eliquis | Apixaban | 32 | 11 |
| Lisinopril | Lisinopril | 32 | 11 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | 12 |
| Atenolol | Atenolol | 25 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162,067.70 · 156 records | Abbott Laboratories | ACCESS, AMPLATZ GOOSE NECK, ASSURANT COBALT, AVVIGO Guidance System, Asahi Peripheral Vascular Wires, CHOCOLATE PTA BALLOON CATHETER, COREVALVE EVOLUT R, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, Dexcom G6 Transmitter, ELUVIA, ESPRIT, General - Atherectomy, General - CT_IC, General - Therapies, HAWKONE, HI-TORQUE COMMAND, MICRA, ONYX FRONTIER, OPTIS, OptiCross, R2P MISAGO, SUPERA, ULTREON, XIENCE V | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error